Advancing Cardiovascular Care of the Oncology Patient

In the United States, an estimated 14.5 million individuals have a history of cancer, representing a prevalent and rapidly growing population that has benefited from remarkable advances in cancer treatment. Given this staggering statistic, clinicians often encounter patients with cancer and cancer survivors who have significant cardiovascular risk factors and cardiovascular disease. For the rapidly evolving cardio-oncology field, The American College of Cardiology presents Advancing Cardiovascular Care of the Oncology Patient, an educational opportunity education offering contemporary care strategies for healthcare providers involved in cardio-vascular care of cancer patients and cancer survivors. Join emerging pioneers in the field of cardio-oncology as they present, through interactive case discussions, debates, breakout sessions and roundtables, evidence-based treatment strategies that address pre, intra and post-chemotherapy heart health.

Overall Goal
The overall goal of this course is to provide clinically relevant, state-of-the-art, best practice strategies in the assessment, diagnosis and management of cardiovascular concerns for patients with cancer and/or those requiring survivorship care.

Learning Objectives

  • Identify common cancer treatment therapies such as anthracyclines, Herceptin, and VEGF inhibitors role in cancer treatment, mechanism of action including cardiotoxicity and resulting cardiovascular disease impact.
  • Recognize appropriate imaging modalities to assess cardiotoxicity, and distinguish the strengths and weaknesses of each cardiac monitoring modality, including echocardiography, strain, CT, MRI, and nuclear imaging
  • Evaluate guidelines from the cardiology and oncology societies and how to incorporate into clinical practice
  • Identify the cardiovascular concerns with newer cancer therapies including strategies for monitoring and treating cardiotoxicity and oncologic therapy
  • Analyze the long-term surveillance and management plan critical for patients who have received high risk systemic therapies such as anthracyclines and those treated with thoracic radiation
  • Evaluate best practices for monitoring patients receiving cardiotoxic cancer therapies and know how to integrate findings into cardiovascular care plans.
  • Identify optimal pharmacologic and lifestyle interventions to be instituted for cancer patients and survivors
  • Identify best practices when developing the cardio-oncology team and building organizational frameworks

Target Audience
The target audience is the cardiologist and cardiovascular advanced team members who are emerging into the field of cardio-oncology, specifically those providing cardiovascular clinical care to patients with cancer and cancer survivors.

Course Directors

Ana Barac, MD, PhD, FACC
Director, Cardio-oncology Program
MedStar Heart and Vascular Institute
Associate Professor of Medicine and Oncology
Georgetown University
Washington, DC 

Bonnie Ky, MD, MSCE, FACC
Assistant Professor of Medicine
Assistant Professor of Epidemiology in Biostatistics and Epidemiology
Perelman School of Medicine at University of Pennsylvania

Content Expert

Anecita Fadol, PhD, RN, FNP, FAANP
Assistant Professor, Department of Nursing
The University of Texas MD Anderson Cancer Center
Houston, TX

Invited Faculty

Saro Armenian, DO, MPH
Associate Professor, Departments of Pediatrics and Population Sciences
Director, Childhood Cancer Survivorship Clinic
Director, Division of Outcomes Research
Department of Population Sciences
City of Hope National Medical Center
Duarte, CA

Gregory Armstrong, MD, MSCE
Associate Member, St. Jude Faculty
Department of Epidemiology and Cancer Control
Division of Neuro Oncology
St. Jude Children's Research Hospital
Memphis, TN

Cathleen Biga, MSN, RN
President, Chief Executive Officer
Cardiovascular Management of Illinois
Woodridge, IL

Chau T. Dang, MD
Chief, West Harrison Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York

Jean-Bernard Durand, MD, FACC
Associate Professor
Department of Cardiology
The University of Texas MD Anderson Cancer Center

Joerg Herrmann, MD
Associate Professor of Medicine
Mayo Clinic
Rochester, MN

W. Gregory Hundley, MD, FACC
Professor, Internal Medicine (Cardiology) and Radiology and
Biomedical Engineering
Wake Forest University School of Medicine
Section of Cardiology
Winston Salem, NC

Richard J. Kovacs, MD, FACC
Professor of Clinical Medicine
Associate Dean for Clinical Research
Indiana University School of Medicine
Clinical Director
Krannert Institute of Cardiology

Monika Jacqueline Leja, MD, FACC
Clinical Assistant Professor
University of Michigan
Ann Arbor, MI

Daniel J. Lenihan, MD, FACC
Director, Clinical Research Program
Vanderbilt Health
Professor of Medicine
Vanderbilt University

Jennifer E. Liu, MD, FACC
Director of Cardiovascular Laboratories
Associate Professor of Clinical Medicine
Memorial Sloan Kettering Cancer Center
New York 

Javid J. Moslehi, MD
Assistant Professor of Medicine
Vanderbilt School of Medicine
Director, Cardio-oncology Program
Vanderbilt-Ingram Cancer Center

Vivek Narayan, MD, MSCE
Assistant Professor of Medicine
Division of Hematology Oncology
Perelman Center for Advanced Medicine

Anju Nohria, MD
Assistant Professor
Harvard Medical School
Brigham and Women's Hospital
Cardiology Division

Mary Norine Walsh, MD, FACC
American College of Cardiology President
Medical Director, Heart Failure and Cardiac Transplantation
St. Vincent Heart Center of Indiana

Ronald Witteles, MD, FACC
Associate Professor of Medicine
Stanford University School of Medicine
Stanford, CA

Myrshia Woods, PA-C
Physician Assistant
The University of Texas MD Anderson Cancer Center

ACCF committee members, faculty, staff and other individuals who are in a position to control the content of this activity are required to disclose all relevant financial relationships he/she and/or his/her spouse or domestic partner has, occurring within the past twelve months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations. Refer to the links below for committee member disclosures and course faculty disclosures. Please note ACCF staff involved with this course have nothing to disclose.

To Register online for the Course please click the Register button at the top of the page.

If you have any special Dietary requirements, please note that this is now captured through your online profile. To enable us to accommodate your request, please ensure that your profile is up to date. If you select the (other) option, a member of our team will be in touch to discuss your needs. If you require assistance, please contact the Resource Center at 800-253-4636, ext. 5603. 

The registration tuition includes educational sessions, continental breakfasts, refreshment breaks, lunch and course materials.

Register me as: Designation Early Until 10/28/17
Advanced 10/29/17 Until 1/20/18
Regular 1/21/18 Until 2/18/18
Member Physician - Includes International Associate
MD, DO PhD $445 $545 $645
Non member Physician - Includes Industry Professional
MD, DO, PhD $675 $775 $875
Member Reduced - Includes CCA Members, CVT, FIT, Resident, Student and Emeritus PA, RN, NP, CNS, PharmD, FIT, Emeritus, Resident, Student
$295 $395 $495
Non-member Reduced PA, RN, NP, CNS, PharmD $399 $499 $599

Optional Pre-conference: Priming Education for the Cardiovascular Clinician: Common Cancer Pharmacotherapies

Friday, February 16, 2018, 4:00 – 6:00 p.m. (Registration at 3:30 p.m.)
Location:  Heart House (2400 N Street, NW, Washington, DC)
Cost: $50 per person

By Popular Demand!  Those attending the optional pre-conference, Priming Education for the Cardiovascular Clinician:  Common Cancer Pharmacotherapies, will be immersed in a two-hour learning opportunity focused on identification of oncology drugs, their role in cancer treatment, the mechanisms of action and strategies to learn more about new drugs in everyday clinical practice.


Cancellation, substitution or transfer to another course is allowed if written notification is received four weeks before a scheduled course. A full refund minus a $250 processing fee will be given for written notifications received fewer than four weeks before the first day of the course. No refund will be given for no-shows.

ACC reserves the right to cancel the course in the unlikely event of insufficient enrollment or other unforeseen circumstances. If a course is canceled or postponed, ACC will refund registration tuition but cannot be held responsible for other costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.

This course has been approved for AMA PRA Category 1 Credits™.

The American College of Cardiology Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Learner Bill of Rights

All sessions will be held at The Ritz-Carlton, Washington DC, 1150 22nd Street, NW, Washington, DC.  The meeting site telephone number is 202-835-0500.


The Ritz-Carlton, Washington DC 1150 22nd Street, NW Washington, DC 20037

Online Reservation Link:
Click here to make your reservations online

Reservations via telephone:
To make a reservation by phone, you can either call the hotel direct at 202-835-0500 or 800--558-9994 and identify yourself as being with the American College of Cardiology/Advancing Cardiovascular Care of the Oncology Patient group.

Room Rates
The ACC negotiated room rate is $229 per night plus state and local taxes (currently 14.5%) per night. The ACC room block is scheduled to be held until January 24, 2018, but may sell out prior to this date. We advise you to register for the course and reserve your lodging as soon as possible.


Please Note
Smoking is prohibited in all ACC meeting rooms.

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us serve you better.

Faculty and course are subject to change without notice.

Accredited status does not imply endorsement by the ANCC or ACC of any commercial products displayed in conjunction with this activity.

The views expressed in this course are those of the individual speaker and do not necessarily reflect the views of the ACC.

Clinical Topics: Cardio-Oncology

Keywords: Cardiotoxicity